News
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback